PharmaCyte Biotech (PMCB) Stock Chart & Stock Price History $1.00 -0.02 (-2.17%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PharmaCyte Biotech Stock Price Performance The PharmaCyte Biotech (PMCB) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 53.92%, with a year-to-date return of -36.31%. In the past month, the stock has decreased 4.31%, reflecting recent market activity. As of the latest close, PharmaCyte Biotech traded at $1.00 with a market cap of $6.86 million and volume of 5,146 shares. Receive PMCB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-3.85%1 Month Performance-4.31%3 Month Performance-36.71%Year-To-Date Performance-36.31%1 Year Performance-53.92% PMCB Stock Chart for Saturday, June, 14, 2025 PMCB Chart by TradingView PharmaCyte Biotech Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/13/2025$1.02$1.00-1.97%$1.03$1.005,146 shs$6.86 million06/12/2025$1.08$1.02-5.55%$1.13$1.019,051 shs$7.00 million06/11/2025$1.08$1.08$1.10$1.056,731 shs$7.41 million06/10/2025$1.04$1.08+3.85%$1.08$1.065,150 shs$7.41 million06/09/2025$1.02$1.04+1.96%$1.06$1.0314,469 shs$7.14 million06/06/2025$1.12$1.02-8.52%$1.12$1.0016,494 shs$7.00 million06/05/2025$1.09$1.12+2.29%$1.14$1.119,181 shs$7.65 million06/04/2025$1.10$1.09-0.91%$1.12$1.059,800 shs$7.48 million06/03/2025$1.07$1.10+2.80%$1.12$1.078,256 shs$7.55 million06/02/2025$1.07$1.07+0.47%$1.09$1.015,627 shs$7.34 million Get the Latest News and Ratings for PMCB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. 05/30/2025$1.02$1.07+4.93%$1.14$1.004,478 shs$7.31 million05/29/2025$1.07$1.02-5.14%$1.05$1.011,993 shs$6.97 million05/28/2025$1.01$1.07+5.92%$1.08$1.0022,486 shs$7.34 million05/27/2025$1.03$1.01-1.54%$1.12$1.0125,090 shs$6.93 million05/26/2025$1.03$1.03$1.05$1.019,957 shs$7.04 million05/23/2025$1.02$1.03+0.59%$1.05$1.019,957 shs$7.04 million05/22/2025$1.04$1.02-1.92%$1.07$1.0113,807 shs$7.00 million05/21/2025$1.04$1.04$1.10$1.042,860 shs$7.14 million05/20/2025$1.03$1.04+0.97%$1.05$1.022,116 shs$7.14 million05/19/2025$1.06$1.03-2.83%$1.15$1.036,869 shs$7.07 million05/16/2025$1.04$1.06+1.92%$1.10$1.0410,842 shs$7.28 million05/15/2025$1.05$1.04-0.48%$1.08$1.014,563 shs$7.14 million05/14/2025$1.05$1.05-0.48%$1.06$1.0017,659 shs$7.17 million05/13/2025$1.06$1.05-0.67%$1.08$1.054,460 shs$7.21 million Related Companies PASG Stock Chart BCAB Stock Chart ALXO Stock Chart ONCY Stock Chart ABVC Stock Chart INKT Stock Chart VOR Stock Chart DARE Stock Chart KALA Stock Chart CVKD Stock Chart Receive PMCB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:PMCB) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
